Precigen Inc Net Assets
Precigen Inc net assets. Based on the latest financial reports, Precigen Inc (PGEN) has net assets worth $43.58 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($170.30 Million) and total liabilities ($126.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See PGEN equity to assets ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $43.58 Million |
| % of Total Assets | 25.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | -80.52% |
| 10-Year Change | -96.33% |
| Growth Volatility | 43.67 |
Net Assets of Precigen Inc (2011–2025)
Net assets of Precigen Inc from 2011 to 2025. This chart illustrates how Precigen Inc's net assets have evolved over time, based on quarterly financial data. Also explore Precigen Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Net Assets for Precigen Inc (2011–2025)
The table below shows the annual net assets of Precigen Inc from 2011 to 2025. For live market cap and overall valuation, see market value of Precigen Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $20.91 Million | -45.70% |
| 2024-12-31 | $38.51 Million | -67.50% |
| 2023-12-31 | $118.50 Million | -6.15% |
| 2022-12-31 | $126.26 Million | +17.62% |
| 2021-12-31 | $107.35 Million | +59.81% |
| 2020-12-31 | $67.17 Million | -6.33% |
| 2019-12-31 | $71.71 Million | -81.07% |
| 2018-12-31 | $378.72 Million | -30.71% |
| 2017-12-31 | $546.54 Million | -3.99% |
| 2016-12-31 | $569.25 Million | -19.24% |
| 2015-12-31 | $704.89 Million | +72.22% |
| 2014-12-31 | $409.29 Million | +7.33% |
| 2013-12-31 | $381.34 Million | +218.59% |
| 2012-12-31 | $-321.55 Million | -45.33% |
| 2011-12-31 | $-221.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Precigen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 212008900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Precigen Inc Net Assets Breakdown (December 2025)
Precigen Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $7.00K | 0.03% |
| Other Components | $2.36 Billion | 11296.70% |
| Total Equity | $20.91 Million | 100.00% |
Precigen Inc Competitors by Market Cap
The table below lists competitors of Precigen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
P/F Bakkafrost
F:6BF
|
$2.44 Billion |
|
Inari Amertron Bhd
KLSE:0166
|
$2.44 Billion |
|
Enerflex Ltd.
NYSE:EFXT
|
$2.44 Billion |
|
People.Cn Co Ltd
SHG:603000
|
$2.44 Billion |
|
BitVentures Limited
NASDAQ:BVC
|
$2.43 Billion |
|
GN Store Nord
CO:GN
|
$2.43 Billion |
|
China Baoan Group Co Ltd
SHE:000009
|
$2.43 Billion |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
$2.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Precigen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 38,513,000 to 20,911,000, a change of -17,602,000 (-45.7%).
- Net loss of 250,642,000 reduced equity.
- Share repurchases of 2,196,000 reduced equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 235,241,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-250.64 Million | -1198.61% |
| Share Repurchases | $2.20 Million | -10.5% |
| Other Comprehensive Income | $-5.00K | -0.02% |
| Other Changes | $235.24 Million | +1124.96% |
| Total Change | $- | -45.70% |
Book Value vs Market Value Analysis
This analysis compares Precigen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 101.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-39.06 | $6.94 | x |
| 2012-12-31 | $-58.11 | $6.94 | x |
| 2013-12-31 | $8.95 | $6.94 | x |
| 2014-12-31 | $3.88 | $6.94 | x |
| 2015-12-31 | $6.25 | $6.94 | x |
| 2016-12-31 | $4.75 | $6.94 | x |
| 2017-12-31 | $4.45 | $6.94 | x |
| 2018-12-31 | $2.80 | $6.94 | x |
| 2019-12-31 | $0.47 | $6.94 | x |
| 2020-12-31 | $0.40 | $6.94 | x |
| 2021-12-31 | $0.54 | $6.94 | x |
| 2022-12-31 | $0.63 | $6.94 | x |
| 2023-12-31 | $0.48 | $6.94 | x |
| 2024-12-31 | $0.14 | $6.94 | x |
| 2025-12-31 | $0.07 | $6.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Precigen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1198.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2588.21%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 7.49x
- Recent ROE (-1198.61%) is below the historical average (-160.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -1064.27% | 0.07x | 0.00x | $-63.15 Million |
| 2012 | 0.00% | -587.96% | 0.09x | 0.00x | $-49.72 Million |
| 2013 | -10.63% | -164.06% | 0.05x | 1.28x | $-75.65 Million |
| 2014 | -21.27% | -113.75% | 0.12x | 1.50x | $-120.30 Million |
| 2015 | -12.17% | -48.67% | 0.18x | 1.41x | $-153.90 Million |
| 2016 | -33.31% | -97.74% | 0.20x | 1.69x | $-242.64 Million |
| 2017 | -21.93% | -50.66% | 0.27x | 1.59x | $-170.38 Million |
| 2018 | -140.37% | -317.20% | 0.22x | 1.97x | $-545.62 Million |
| 2019 | -237.79% | -533.01% | 0.07x | 6.36x | $-177.69 Million |
| 2020 | -253.85% | -533.01% | 0.10x | 4.68x | $-177.24 Million |
| 2021 | -85.86% | -646.01% | 0.04x | 3.35x | $-102.90 Million |
| 2022 | 22.43% | 105.23% | 0.12x | 1.71x | $15.69 Million |
| 2023 | -80.93% | -1540.63% | 0.04x | 1.27x | $-107.75 Million |
| 2024 | -327.77% | -3216.18% | 0.03x | 3.77x | $-130.09 Million |
| 2025 | -1198.61% | -2588.21% | 0.06x | 7.49x | $-252.73 Million |
Industry Comparison
This section compares Precigen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Precigen Inc (PGEN) | $43.58 Million | 0.00% | 2.91x | $2.43 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more